Thursday, July 14, 2022

Tuesday, July 12, 2022

Catherine joins Cochrane from The Seafarers’ Charity where she held the position of CEO.

Governing Board Co-Chairs, Tracey Howe and Catherine Marshall said: "We are delighted to welcome Catherine to Cochrane. Catherine is a proven Chief Executive with an exceptional record leading non-profit organisations. She brings expertise in strategic planning, change management, and communications under pinned by a global perspective. Catherine is well positioned to partner with the Editor-in-Chief, Karla Soares-Weiser, to lead Cochrane as we drive an exciting programme of delivering trusted evidence, promoting informed decisions, and better health.”

Prior to her role at The Seafarers’ Charity, Catherine was acting Chief Operating Officer and Director of Communications and Change Management at international public health research organisation, icddrb, in Dhaka, Bangladesh. Between 2008-2015 Catherine held various senior management roles at the Army Families Federation, including three years as Chief Executive.

Catherine Spencer said, “Like all organisations post-Covid, we have challenges to deal with, but I see so much opportunity for Cochrane in the future. I look forward to what will inevitably be stimulating conversations with the Cochrane Community about what a thriving future Cochrane looks like and what we need to do to achieve that as we build a long-term strategy together.

I spent three and a half years working at icddr,b, in Dhaka, Bangladesh - a large public health research organisation, that at the time was facing enormous financial and structural challenge. Working as part of the Senior Leadership Team, and very closely with the Executive Director and Board, the organization was rejuvenated, meaning its essential public health research could continue. Thus, I come to Cochrane familiar with an organisation managing change and I look forward to working with you, collaboratively to steer Cochrane to success.”

Catherine will meet with the Cochrane Community in two introductory webinars to accommodate different time zones. Invites will be sent directly to Community Members via email.

• Read Catherine's full bio

 

Tuesday, July 12, 2022

Jesu li antipsihotici sigurni i učinkoviti u liječenju osoba koje imaju poremećaje iz spektra shizofrenije sa simptomima katatonije? Ključne poruke - Nismo mogli odgovoriti na pitanje jesu li antipsihotici sigurni i učinkoviti za poremećaje iz spektra shizofrenije sa simptomima katatonije jer smo pronašli samo jedno istraživanje koje je uključilo mali broj osoba te je imalo kratki period trajanja liječenja, a to je dovelo do vrlo niske pouzdanosti u rezultate. - Otkrili smo da u jedinom uključenom istraživanju i antipsihotik (risperidon) i elektrokonvulzivna terapija mogu poboljšati simptome...

Intervencije za liječenje osteonekroze čeljusti (teškog oštećenja kosti) povezane s lijekovima Istraživačko pitanje Kakvi su učinci različitih intervencija za sprječavanje ili liječenje osteonekroze čeljusti povezane s lijekovima? Dosadašnje spoznaje Osteonekroza čeljusti povezana s lijekovima (engl. medication-related osteonecrosis of the jaw, MRONJ) ozbiljno je oštećenje čeljusne kosti koje se javlja u nekih ljudi kao reakcija na određene lijekove koji se obično koriste u liječenju raka i osteoporoze (bolesti koja kosti čini lomljivima). To je bolno stanje koje je teško liječiti. Rijetko...

Koliko je dupleks ultrazvuk (DUZV) točan u dijagnosticiranju stenoze karotidne arterije u simptomatskih pacijenata? Stenoza karotidnih arterija je suženje lumena (unutrašnjeg promjera) karotidne arterije (najčešće kao posljedica naslaga kolesterola zvanih plak). Stenoza karotidnih arterija odgovorna je za 8% svih ishemijskih moždanih udara (uzrokovanih začepljenjem krvne žile) i povezana je s visokom vjerojatnošću recidiva. Terapijski se pristup u tim okolnostima sastoji od ponovne uspostave adekvatnog protoka krvi (kirurškim ili drugim metodama ponovnog uspostavljanja prohodnosti arterije)...

Obuka o zaštiti djece u svrhu poboljšanja prijava zlostavljanja i zanemarivanja djece Ključne poruke - Zbog nedostatka čvrstih dokaza, nije jasno je li obuka o zaštiti djece bolja od nikakve obuke ili alternativne obuke (npr. obuke o kulturološkoj osjetljivosti) u poboljšanju prijava o zlostavljanju i zanemarivanju djece od strane stručnjaka. - Potrebna su veća, dobro osmišljena ispitivanja za procjenu učinaka obuke sa širim rasponom profesionalnih skupina. - Buduća istraživanja bi trebala usporediti intervencije uživo i one provedene putem elektronskog učenja. Zašto trebamo poboljšati...

Periimplantacijska primjena glukokortikoida za cikluse potpomognute oplodnje Cilj sustavnog pregleda Ovaj pregled je istraživao je li primjena glukokortikoida u vrijeme implantacije embrija poboljšala mogućnost trudnoće kod žena koje su podvrgnute in vitro oplodnji (IVF) ili intracitoplazmatskoj injekciji spermija (ICSI) u usporedbi s nedavanjem glukokortikoida. IVF i ICSI su tretmani koji pomažu u postizanju trudnoće. Dosadašnje spoznaje Glukokortikoidi su klasa lijekova koji su slični steroidnim hormonima koji se prirodno stvaraju u tijelu. Ovi lijekovi smanjuju upalu i potiskuju imunosni...

Certolizumab pegol za održavanje neaktivne Crohnove bolesti Cilj Cochraneovog sustavnog pregleda Ovaj Cochraneov sustavni pregled imao je za cilj otkriti je li dugotrajna uporaba certolizumab pegola (CZP) učinkovit i siguran oblik liječenja za osobe s Crohnovom bolešću (CB) u usporedbi s placebom. Da bismo odgovorili na ovo pitanje, prikupili smo i analizirali sva relevantna istraživanja. Što je Crohnova bolest? Crohnova bolest je kronična bolest koja uzrokuje upalu gastrointestinalnog sustava kao što su tanko i debelo crijevo. Uobičajeni simptomi Crohnove bolesti su kronični proljev,...

Liječenje moždanog udara omega-3 masnim kiselinama dobivenim iz mora Istraživačko pitanje Kakvi su učinci omega-3 masnih kiselina morskog podrijetla u liječenju moždanog udara u kraćem (do 3 mjeseca) i duljem (više od 3 mjeseca) praćenju? Dosadašnje spoznaje Moždani udar odnosi se na skupinu bolesti koje zahvaćaju krvne žile mozga. Moždani udar može nastati krvarenjem ili začepljenjem krvnih žila u mozgu što dovodi do gubitka funkcije moždanih stanica. Prolazni ishemijski napad (engl. Transient ischaemic attack, TIA) poznat i kao „mali moždani udar“ prolazni je poremećaj krvne opskrbe mozga....

Specifications: Full Time (Permanent)
Salary: circa £40,000 per annum
Location: Ideally based in the UK, Germany or Denmark. Candidates from the rest of the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries (1-year fixed-term contracts)
Application Closing Date: 7th September 2022

 

Cochrane has established a centrally-resourced Editorial Service to support the efficient and timely publication of high-quality systematic reviews in the Cochrane Library. The reviews that are published through the Central Editorial Service address some of the research questions considered to be the most important to decision makers.

Reporting to the Executive Editor of the Central Editorial Service, the Managing Editor will manage the editorial process of protocols and reviews submitted to the Central Editorial Service. The role-holder should be alert to the demands of delivering high-quality review content for publication in a timely fashion, and work to ensure that deadlines can be met.   

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information. An understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible locations are possible for the right candidate. Please note, however, that we are only able to offer consultancy contracts outside of the UK, Germany or Denmark.

We will consider extended notice periods if required for applicants who wish to honour existing contracts. We fully support remote and flexible working arrangements. 

How to apply

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is by 7th September. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
• Read our Recruitment Privacy Statement

Thursday, August 18, 2022 Category: Jobs

Specifications: Permanent
Salary: £45,000 per annum
Location: UK
Application Closing Date:  17 July 2022

To provide strategic support to deliver cross-departmental objectives and targets by:

• Working closely with the Editorial Product Lead and the methods community to deliver on activities so Cochrane can produce and publish a variety of evidence synthesis types and other content that align with Cochrane’s strategy for review production and meet Cochrane’s mission.
• Coordinating the development of best practice resources for Cochrane’s methodological standards.
• Leading on editorial and methods projects to develop Cochrane’s platforms and processes.
• Being the main point of contact for the methods community and engaging with Methods Groups, the Methods Executive and Methods Network to facilitate their involvement with Cochrane.

The Methods Implementation Editor will provide strategic editorial and methods support to departments across Cochrane and the methods community to enable efficient, high-quality review production for a variety of types of evidence syntheses and methods. Overall, this role will contribute to streamlining and simplifying review production and publication to support Cochrane’s efficiency and sustainability as an organisation.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is by 17 July 2022.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
• Read our Recruitment Privacy Statement

 

Tuesday, June 28, 2022 Category: Jobs

Liječenje svih zuba (cijelih usta) unutar 24 sata za bolesti desni (parodontitisa) u odraslih Dosadašnje spoznaje Dugotrajna bolest desni (parodontitis) česta je kronična upalna bolest koja uzrokuje oštećenje mekih tkiva (desni) i kosti oko zuba, a može dovesti do gubitka zuba. Za zaustavljanje i kontrolu bolesti koriste se nekirurški oblici liječenja. Oni se temelje na 'subgingivalnoj instrumentaciji', odnosno mehaničkom uklanjanju bakterija ispod zubnog mesa s inficiranih površina korijena zuba. Standardno liječenje provodi se u dvije do četiri sesije tijekom nekoliko tjedana, pri čemu se...

Liječenje svih zuba (cijelih usta) unutar 24 sata za bolesti desni (parodontitis) kod odraslih Dosadašnje spoznaje Dugotrajna bolest desni (parodontitis) česta je kronična upalna bolest koja uzrokuje oštećenje mekih tkiva (desni) i kosti oko zuba, a može dovesti do gubitka zuba. Za zaustavljanje i kontrolu bolesti koriste se nekirurški oblici liječenja. Oni se temelje na 'subgingivalnoj instrumentaciji', odnosno mehaničkom uklanjanju bakterija ispod zubnog mesa s inficiranih površina korijena zuba. Standardno liječenje provodi se u dvije do četiri sesije tijekom nekoliko tjedana, pri čemu se...

Inhalacijski kratkodjelujući bronhodilatatori za cističnu fibrozu Cilj sustavnog pregleda Pregledali smo dokaze o korištenju kratkodjelujućih inhalacijskih bronhodilatatora (lijekova koji šire i otvaraju dišne puteve, olakšavajući disanje) kod osoba s cističnom fibrozom. Djelovanje kratkodjelujućih bronhodilatatora započinje brzo i obično traje 4-6 sati. Zanimala nas je bilo koja vrsta kratkodjelujućeg inhalacijskog bronhodilatatora, dana u bilo kojoj dozi i bilo kojom vrstom uređaja (inhalator ili nebulizator). I nebulizatori i inhalatori isporučuju lijek. Nebulizatori pretvaraju tekući...

Cochrane Sustainable Healthcare and Choosing Wisely Canada invite you to join a free live webinar where leading experts discuss the challenges of abandoning existing low-value care practices, which may not be beneficial or even cause harm to patients. Ideal for healthcare professionals, guideline developers, and policy makers.

Experts will share experiences on how to address the urgency of finding out when and how de-implementation, de-intensification of medical interventions, and diagnostics should be undertaken, without causing harm to patients, de-professionalizing clinicians, or counteracting shared decision-making processes.

 10 Oct 2022
4:00pm - 5:30pm CET (View in your time zone) 
View agenda
Register for free

Speakers:

• Dr. Minna Johansson, Cochrane Sustainable Healthcare  and Cochrane Sweden
• Dr. Wendy Levinson, Choosing Wisely Canada
• Dr. Jeremy Grimshaw, Choosing Wisely Canada
• Dr. Nicolaas Sieds Klazinga, OECD Health Care Quality Indicator

 

Tuesday, October 4, 2022

Specifications: 12 months Fixed term/Consultancy contract dependant on location
Salary: £42,000 per annum
Location: Flexible
Application Closing Date:  12 August 2022

Cochrane requires a talented internal communications specialist to contribute to the development and implementation of a complex, organization-wide transformation and change management programme to be rolled out over the next 12 months. The key focus of this varied role will be creating and delivering a strategic internal communications plan to support our ongoing transformation programmes. This will involve creating and disseminating clear, informative and engaging content (including online news and social media posts, videos and e-newsletters) for the Cochrane community and the many diverse audiences within it.

Cochrane manages a large number of websites and social media channels. The organisation also uses a digital marketing database for targeted mailings and newsletters; and can segment audiences to ensure effective communication.

This role would suit an individual who embraces change; whilst understanding how to convey key messages to stakeholder groups impacted by this change.

Cochrane is a global network of more than 115,000 people, and our internal community accounts for around 1,000 of those people. This role will need to work effectively across the internal community network, demonstrating excellent cross-cultural working. 

How to apply

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is by 12 August 2022. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
• Read our Recruitment Privacy Statement 

Monday, August 1, 2022 Category: Jobs

Antibiotici u liječenju nekompliciranog divertikulitisa Divertikulitis predstavlja stanje s upalom hernijacija (nazvanih divertikuli) debelog crijeva. Divertikul je slabost stijenke crijeva. Divertikuli su česti u populaciji, osobito u starijih osoba iznad 60 godina, a često su asimptomatski. Divertikulitis se može manifestirati kao osjetljivost i bol u trbuhu popraćena znakovima infekcije, poput vrućice. U većini slučajeva, divertikulitis prolazi bez komplikacija, međutim, neki pacijenti razviju komplikacije koje zahtijevaju hitan kirurški zahvat. Fokus ovog sustavnog pregleda je...

Is ivermectin effective for COVID‐19? Updated Cochrane review 'Ivermectin for preventing and treating COVID‐19'

Key messages

• We found no evidence to support the use of ivermectin for treating COVID‐19 or preventing SARS‐CoV‐2 infection. The evidence base improved slightly in this update, but is still limited.
• Evaluation of ivermectin is continuing in 31 ongoing trials, and we will update this review again when their results become available.  

What is ivermectin?
Ivermectin is a medicine used to treat parasites, such as intestinal parasites in animals, and scabies in humans. It is inexpensive and is widely used in regions of the world where parasitic infestations are common. It has few unwanted effects.  

Medical regulators have not approved ivermectin for COVID‐19.

What did we want to find out?
We wanted to update our knowledge of whether ivermectin reduces death, illness, and length of infection in people with COVID‐19, or is useful in prevention of the infection. We included trials comparing the medicine to placebo (dummy treatment), usual care, or treatments for COVID‐19 that are known to work to some extent, such as dexamethasone. We excluded trials comparing ivermectin to other medicines that do not work, like hydroxychloroquine, or whose effectiveness against COVID‐19 is uncertain.

We evaluated the effects of ivermectin in infected people on:

• people dying;
• whether people's COVID‐19 got better or worse;
• quality of life;
• serious and non‐serious unwanted effects;
• viral clearance.

For prevention, we sought the effect on preventing SARS‐CoV‐2 infection and COVID‐19 disease.

What did we do?
We searched for randomized controlled trials that investigated ivermectin to prevent or treat COVID‐19. People treated in hospital or as outpatients had to have laboratory‐confirmed COVID‐19.

In this update, we also investigated the trustworthiness of the trials and only included them if they fulfilled clear ethical and scientific criteria.

We compared and summarized the results of the trials and rated our confidence in the evidence, based on common criteria such as trial methods and sizes.

What did we find?
We excluded seven of the 14 trials included in the previous review as these trials did not fulfil the expected ethical and scientific criteria. Together with four new trials, we included 11 trials with 3409 participants that investigated ivermectin combined with any usual care compared to the same usual care or placebo.

For treatment, there were five trials of people in hospital with moderate COVID‐19 and six trials of outpatients with mild COVID‐19. The trials used different doses of ivermectin and different durations of treatment.  

No trial investigated ivermectin to prevent SARS‐CoV‐2 infection.

We also found 31 ongoing trials, and an additional 28 trials still requiring clarification from the authors or not yet published.

Main results  

Treating people in hospital with COVID‐19

We do not know whether ivermectin compared with placebo or usual care 28 days after treatment:

• leads to more or fewer deaths (3 trials, 230 people);
• worsens or improves patients' condition, assessed by need for ventilation or death (2 trials, 118 people);
• increases or reduces serious unwanted events (2 trials, 197 people).

Ivermectin compared with placebo or usual care 28 days after treatment, may make little or no difference to:

• improving patients' condition, assessed by discharge from hospital (1 trial, 73 people);
• non‐serious unwanted events (3 trials, 228 participants). 

Seven days after treatment, ivermectin may make little or no difference to reduction of negative COVID‐19 tests (3 trials, 231 participants) compared with placebo or usual care.

Treating outpatients with COVID‐19
Ivermectin compared with placebo or usual care 28 days after treatment, probably makes little or no difference to people dying (6 trials, 2860 people).

Ivermectin compared with placebo or usual care 28 days after treatment, makes little or no difference to quality of life (1 trial, 1358 people).

Ivermectin compared with placebo or usual care 28 days after treatment, may make little or no difference to:

• worsening patients' condition, assessed by admission to hospital or death (2 trials, 590 people);
• serious unwanted events (5 trials, 1502 people);
• non‐serious unwanted events (5 trials, 1502 participants);
• improving people's COVID‐19 symptoms in the 14 days after treatment (2 trials, 478 people);
• number of people with negative COVID‐19 tests 7 days after treatment (2 trials, 331 people).

Review authors, Dr Maria Popp and Dr Stephanie Weibel said:

“Overall, the outlook for ivermectin’s use to treat or prevent SARS-CoV-2 is poor. While laboratory results showed some promise, real-life outcomes suggest no or very little impact on mortality rates, illness, and length of infection.”

What are the limitations of the evidence?
Our confidence in the evidence, especially for outpatients, improved since the last review version, because we could look at more participants included in high‐quality trials. Although we are quite certain regarding our results on risk of people dying and quality of life, the confidence in the evidence is still low for many other outpatient and inpatient outcomes because there were only few events measured. The methods differed between trials, and they did not report everything we were interested in, such as relevant outcomes.

How up to date is this evidence?
The systematic literature search is up to date to 16 December 2021. Additionally, we included trials with > 1000 participants up to April 2022.

• Link to updated review
• Link to Liverpool School of Tropical Medicine news item

 

Wednesday, June 22, 2022

Koji su najbolji načini liječenja odraslih s prijelomom ramena? Ključne poruke - Nema dovoljno dokaza koji bi pokazali utječe li rano pokretanje ruke u zavoju nakon tjedan dana na dugoročnu funkciju ramena ili na razvoj problema s ramenom u usporedbi s držanjem ruke u zavoju tri ili više tjedana. - Pacijenti navode da kirurški zahvati ne dovode do bolje funkcije ramena za većinu vrsta prijeloma s pomakom (gdje su se slomljeni dijelovi razmaknuli) od nekirurškog liječenja. Međutim, to može dovesti do većeg rizika od naknadne operacije zbog komplikacija. - U slučaju operativnog liječenja, nema...